{"id":4786,"date":"2024-11-29T10:14:54","date_gmt":"2024-11-29T09:14:54","guid":{"rendered":"https:\/\/cnatm-1.betapage.de\/?p=4786"},"modified":"2024-12-10T10:14:58","modified_gmt":"2024-12-10T09:14:58","slug":"eisbachbio-erhaelt-crpit-grant-zur-foerderung-neuer-krebsmedikamente","status":"publish","type":"post","link":"https:\/\/cnatm.de\/en\/eisbachbio-erhaelt-crpit-grant-zur-foerderung-neuer-krebsmedikamente\/","title":{"rendered":"Eisbach Bio erh\u00e4lt CRPIT Grant zur F\u00f6rderung neuer Krebsmedikamente"},"content":{"rendered":"
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Eisbach Bio GmbH receives CRPIT Grant to promote new cancer drugs<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

LMU spin-off Eisbach Bio GmbH has received a Texas Therapeutics Company Award from the Cancer Prevention and Research Institute of Texas (CPRIT). This grant will support the clinical development of EIS-12656, which targets challenging cancers with homologous recombination defects (HRD). Eisbach Bio GmbH had previously secured $4.5 million in funding in June 2024. Juni 2024 4,5 Mio $ F\u00f6rdermittel<\/a> gesichert.<\/p>

Read more<\/a><\/p>

Grant Information<\/a><\/p>

\u00a0<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"Eisbach\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

Eisbach Bio GmbH erh\u00e4lt CRPIT Grant zur F\u00f6rderung neuer Krebsmedikamente Die LMU Ausgr\u00fcndung Eisbach Bio GmbH hat einen Texas Therapeutics Company Award vom Cancer Prevention and Research Institute of Texas (CPRIT) erhalten. Dieser Zuschuss wird die klinische Entwicklung von EIS-12656 unterst\u00fctzen, das auf anspruchsvolle Krebsarten mit homologen Rekombinationsdefekten (HRD) abzielt. Zuvor hatte die Eisbach Bio […]<\/p>","protected":false},"author":11,"featured_media":4772,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[62],"tags":[],"class_list":["post-4786","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"acf":[],"yoast_head":"\nEisbach Bio erh\u00e4lt CRPIT Grant zur F\u00f6rderung neuer Krebsmedikamente - CNATM<\/title>\n<meta name=\"description\" content=\"Die Eisbach Bio GmbH hat einen Texas Therapeutics Company Award vom Cancer Prevention and Research Institute of Texas (CPRIT) erhalten.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cnatm.de\/en\/eisbachbio-erhaelt-crpit-grant-zur-foerderung-neuer-krebsmedikamente\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eisbach Bio erh\u00e4lt CRPIT Grant zur F\u00f6rderung neuer Krebsmedikamente - CNATM\" \/>\n<meta property=\"og:description\" content=\"Die Eisbach Bio GmbH hat einen Texas Therapeutics Company Award vom Cancer Prevention and Research Institute of Texas (CPRIT) erhalten.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cnatm.de\/en\/eisbachbio-erhaelt-crpit-grant-zur-foerderung-neuer-krebsmedikamente\/\" \/>\n<meta property=\"og:site_name\" content=\"CNATM\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-29T09:14:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-10T09:14:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cnatm.de\/wp-content\/uploads\/2024\/11\/Eisbach_Bio_GmbH.png\" \/>\n\t<meta property=\"og:image:width\" content=\"2000\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Patrizia Torelli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Patrizia Torelli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cnatm.de\/eisbachbio-erhaelt-crpit-grant-zur-foerderung-neuer-krebsmedikamente\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/cnatm.de\/eisbachbio-erhaelt-crpit-grant-zur-foerderung-neuer-krebsmedikamente\/\"},\"author\":{\"name\":\"Patrizia Torelli\",\"@id\":\"https:\/\/cnatm.de\/#\/schema\/person\/f2fc8eccad93916c1b891b5fef1ac19e\"},\"headline\":\"Eisbach Bio erh\u00e4lt CRPIT Grant zur F\u00f6rderung neuer Krebsmedikamente\",\"datePublished\":\"2024-11-29T09:14:54+00:00\",\"dateModified\":\"2024-12-10T09:14:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cnatm.de\/eisbachbio-erhaelt-crpit-grant-zur-foerderung-neuer-krebsmedikamente\/\"},\"wordCount\":85,\"publisher\":{\"@id\":\"https:\/\/cnatm.de\/#organization\"},\"image\":{\"@id\":\"https:\/\/cnatm.de\/eisbachbio-erhaelt-crpit-grant-zur-foerderung-neuer-krebsmedikamente\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cnatm.de\/wp-content\/uploads\/2024\/11\/Eisbach_Bio_GmbH.png\",\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cnatm.de\/eisbachbio-erhaelt-crpit-grant-zur-foerderung-neuer-krebsmedikamente\/\",\"url\":\"https:\/\/cnatm.de\/eisbachbio-erhaelt-crpit-grant-zur-foerderung-neuer-krebsmedikamente\/\",\"name\":\"Eisbach Bio erh\u00e4lt CRPIT Grant zur F\u00f6rderung neuer Krebsmedikamente - CNATM\",\"isPartOf\":{\"@id\":\"https:\/\/cnatm.de\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cnatm.de\/eisbachbio-erhaelt-crpit-grant-zur-foerderung-neuer-krebsmedikamente\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cnatm.de\/eisbachbio-erhaelt-crpit-grant-zur-foerderung-neuer-krebsmedikamente\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cnatm.de\/wp-content\/uploads\/2024\/11\/Eisbach_Bio_GmbH.png\",\"datePublished\":\"2024-11-29T09:14:54+00:00\",\"dateModified\":\"2024-12-10T09:14:58+00:00\",\"description\":\"Die Eisbach Bio GmbH hat einen Texas Therapeutics Company Award vom Cancer Prevention and Research Institute of Texas (CPRIT) erhalten.\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cnatm.de\/eisbachbio-erhaelt-crpit-grant-zur-foerderung-neuer-krebsmedikamente\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cnatm.de\/eisbachbio-erhaelt-crpit-grant-zur-foerderung-neuer-krebsmedikamente\/#primaryimage\",\"url\":\"https:\/\/cnatm.de\/wp-content\/uploads\/2024\/11\/Eisbach_Bio_GmbH.png\",\"contentUrl\":\"https:\/\/cnatm.de\/wp-content\/uploads\/2024\/11\/Eisbach_Bio_GmbH.png\",\"width\":2000,\"height\":600,\"caption\":\"Eisbach Bio GmbH\"},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cnatm.de\/#website\",\"url\":\"https:\/\/cnatm.de\/\",\"name\":\"CNATM\",\"description\":\"Cluster for Nucleic Acid Therapeutics Munich\",\"publisher\":{\"@id\":\"https:\/\/cnatm.de\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cnatm.de\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cnatm.de\/#organization\",\"name\":\"CNATM\",\"url\":\"https:\/\/cnatm.de\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cnatm.de\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cnatm.de\/wp-content\/uploads\/2022\/02\/CNATM-Logo-mit-Zusatz-RGB-bunt-schwarz.jpg\",\"contentUrl\":\"https:\/\/cnatm.de\/wp-content\/uploads\/2022\/02\/CNATM-Logo-mit-Zusatz-RGB-bunt-schwarz.jpg\",\"width\":2362,\"height\":479,\"caption\":\"CNATM\"},\"image\":{\"@id\":\"https:\/\/cnatm.de\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/cnatm.de\/#\/schema\/person\/f2fc8eccad93916c1b891b5fef1ac19e\",\"name\":\"Patrizia Torelli\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cnatm.de\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/87ab0132dfbaaa804847124811e093cdf95fa3b96905aba129559c779a1ff8eb?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/87ab0132dfbaaa804847124811e093cdf95fa3b96905aba129559c779a1ff8eb?s=96&d=mm&r=g\",\"caption\":\"Patrizia Torelli\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Eisbach Bio erh\u00e4lt CRPIT Grant zur F\u00f6rderung neuer Krebsmedikamente - CNATM","description":"Die Eisbach Bio GmbH hat einen Texas Therapeutics Company Award vom Cancer Prevention and Research Institute of Texas (CPRIT) erhalten.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cnatm.de\/en\/eisbachbio-erhaelt-crpit-grant-zur-foerderung-neuer-krebsmedikamente\/","og_locale":"en_US","og_type":"article","og_title":"Eisbach Bio erh\u00e4lt CRPIT Grant zur F\u00f6rderung neuer Krebsmedikamente - CNATM","og_description":"Die Eisbach Bio GmbH hat einen Texas Therapeutics Company Award vom Cancer Prevention and Research Institute of Texas (CPRIT) erhalten.","og_url":"https:\/\/cnatm.de\/en\/eisbachbio-erhaelt-crpit-grant-zur-foerderung-neuer-krebsmedikamente\/","og_site_name":"CNATM","article_published_time":"2024-11-29T09:14:54+00:00","article_modified_time":"2024-12-10T09:14:58+00:00","og_image":[{"width":2000,"height":600,"url":"https:\/\/cnatm.de\/wp-content\/uploads\/2024\/11\/Eisbach_Bio_GmbH.png","type":"image\/png"}],"author":"Patrizia Torelli","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Patrizia Torelli","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cnatm.de\/eisbachbio-erhaelt-crpit-grant-zur-foerderung-neuer-krebsmedikamente\/#article","isPartOf":{"@id":"https:\/\/cnatm.de\/eisbachbio-erhaelt-crpit-grant-zur-foerderung-neuer-krebsmedikamente\/"},"author":{"name":"Patrizia Torelli","@id":"https:\/\/cnatm.de\/#\/schema\/person\/f2fc8eccad93916c1b891b5fef1ac19e"},"headline":"Eisbach Bio erh\u00e4lt CRPIT Grant zur F\u00f6rderung neuer Krebsmedikamente","datePublished":"2024-11-29T09:14:54+00:00","dateModified":"2024-12-10T09:14:58+00:00","mainEntityOfPage":{"@id":"https:\/\/cnatm.de\/eisbachbio-erhaelt-crpit-grant-zur-foerderung-neuer-krebsmedikamente\/"},"wordCount":85,"publisher":{"@id":"https:\/\/cnatm.de\/#organization"},"image":{"@id":"https:\/\/cnatm.de\/eisbachbio-erhaelt-crpit-grant-zur-foerderung-neuer-krebsmedikamente\/#primaryimage"},"thumbnailUrl":"https:\/\/cnatm.de\/wp-content\/uploads\/2024\/11\/Eisbach_Bio_GmbH.png","articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/cnatm.de\/eisbachbio-erhaelt-crpit-grant-zur-foerderung-neuer-krebsmedikamente\/","url":"https:\/\/cnatm.de\/eisbachbio-erhaelt-crpit-grant-zur-foerderung-neuer-krebsmedikamente\/","name":"Eisbach Bio erh\u00e4lt CRPIT Grant zur F\u00f6rderung neuer Krebsmedikamente - CNATM","isPartOf":{"@id":"https:\/\/cnatm.de\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cnatm.de\/eisbachbio-erhaelt-crpit-grant-zur-foerderung-neuer-krebsmedikamente\/#primaryimage"},"image":{"@id":"https:\/\/cnatm.de\/eisbachbio-erhaelt-crpit-grant-zur-foerderung-neuer-krebsmedikamente\/#primaryimage"},"thumbnailUrl":"https:\/\/cnatm.de\/wp-content\/uploads\/2024\/11\/Eisbach_Bio_GmbH.png","datePublished":"2024-11-29T09:14:54+00:00","dateModified":"2024-12-10T09:14:58+00:00","description":"Die Eisbach Bio GmbH hat einen Texas Therapeutics Company Award vom Cancer Prevention and Research Institute of Texas (CPRIT) erhalten.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cnatm.de\/eisbachbio-erhaelt-crpit-grant-zur-foerderung-neuer-krebsmedikamente\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cnatm.de\/eisbachbio-erhaelt-crpit-grant-zur-foerderung-neuer-krebsmedikamente\/#primaryimage","url":"https:\/\/cnatm.de\/wp-content\/uploads\/2024\/11\/Eisbach_Bio_GmbH.png","contentUrl":"https:\/\/cnatm.de\/wp-content\/uploads\/2024\/11\/Eisbach_Bio_GmbH.png","width":2000,"height":600,"caption":"Eisbach Bio GmbH"},{"@type":"WebSite","@id":"https:\/\/cnatm.de\/#website","url":"https:\/\/cnatm.de\/","name":"CNATM","description":"Cluster for Nucleic Acid Therapeutics Munich","publisher":{"@id":"https:\/\/cnatm.de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cnatm.de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cnatm.de\/#organization","name":"CNATM","url":"https:\/\/cnatm.de\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cnatm.de\/#\/schema\/logo\/image\/","url":"https:\/\/cnatm.de\/wp-content\/uploads\/2022\/02\/CNATM-Logo-mit-Zusatz-RGB-bunt-schwarz.jpg","contentUrl":"https:\/\/cnatm.de\/wp-content\/uploads\/2022\/02\/CNATM-Logo-mit-Zusatz-RGB-bunt-schwarz.jpg","width":2362,"height":479,"caption":"CNATM"},"image":{"@id":"https:\/\/cnatm.de\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/cnatm.de\/#\/schema\/person\/f2fc8eccad93916c1b891b5fef1ac19e","name":"Patrizia Torelli","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cnatm.de\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/87ab0132dfbaaa804847124811e093cdf95fa3b96905aba129559c779a1ff8eb?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/87ab0132dfbaaa804847124811e093cdf95fa3b96905aba129559c779a1ff8eb?s=96&d=mm&r=g","caption":"Patrizia Torelli"}}]}},"_links":{"self":[{"href":"https:\/\/cnatm.de\/en\/wp-json\/wp\/v2\/posts\/4786","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cnatm.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cnatm.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cnatm.de\/en\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/cnatm.de\/en\/wp-json\/wp\/v2\/comments?post=4786"}],"version-history":[{"count":18,"href":"https:\/\/cnatm.de\/en\/wp-json\/wp\/v2\/posts\/4786\/revisions"}],"predecessor-version":[{"id":4939,"href":"https:\/\/cnatm.de\/en\/wp-json\/wp\/v2\/posts\/4786\/revisions\/4939"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cnatm.de\/en\/wp-json\/wp\/v2\/media\/4772"}],"wp:attachment":[{"href":"https:\/\/cnatm.de\/en\/wp-json\/wp\/v2\/media?parent=4786"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cnatm.de\/en\/wp-json\/wp\/v2\/categories?post=4786"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cnatm.de\/en\/wp-json\/wp\/v2\/tags?post=4786"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}